Sanofi's Dupixent has set a high standard of care, generating a market value exceeding $10 billion while treating less than 10% of the moderate-to-severe AD patient population. B.Riley suggests ...

Dupixent is generally dosed every two or four weeks for AD. At the American Academy of Dermatology (AAD) congress in San Diego, data from STEAM-AD showed that amlitelimab achieved sustained ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

Sanofi's Dupixent has set a high standard of care, generating a market value exceeding $10 billion while treating less than 10% of the moderate-to-severe AD patient population. B.Riley suggests that ...